第三條 委員會對董事會負責，並向董事會報告工作。 第四條 本細則適用於委員會及本細則中涉及的有關人員和部門。 第二章 委員會組成 第五條 委員會由不少於三名董事組成，且應僅由非執行董事組成，其中獨 立非執行董事應過半數。委員會委員應當具備與其職責相適應的財務或者法律等 方面的專業知識和商業經驗。應至少有一名成員為具備適當的專業資格、會計或 相關的財務管理專長之獨立非執行董事，符合《香港上市規則》對審計委員會財務 專業人士的資格要求。 所謂「適當的會計或相關的財務管理專長」，指有關人士透過從事執業會計師 或核數師或是公眾公司的財務總監或首席會計主任等工作又或履行類似職能的經 驗，而具備內部監控以及編製或審計可資比較的財務報表的經驗，或是分析公眾 公司經審計財務報表的經驗。董事會有責任根據個別情況決定個別人士是否勝任 人選。在作出決定的過程中，董事會必須總體衡量個別人士的教育及經驗。 1 長風藥業股份有限公司 審計委員會職責和議事規則 第一章 總則 第一條 為建立和規範長風藥業股份有限公司（以下簡稱「公司」）審計制度和 程序，強化董事會（以下簡稱「董事會」）決策功能，確保董事會對經理層的有效監 督，完善公司治理結 ...

長風藥業股份有限公司章程 1 | 第一章 | 總則 | 3 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 4 | | 第三章 | 股份 | 5 | | 第一節 | 股份發行 | 5 | | 第二節 | 股份增減和回購 | 7 | | 第三節 | 股份轉讓 | 9 | | 第四章 | 股東和股東會 | 10 | | 第一節 | 股東 | 10 | | 第二節 | 股東會的一般規定 | 15 | | 第三節 | 股東會的召集 | 18 | | 第四節 | 股東會的提案與通知 | 19 | | 第五節 | 股東會的召開 | 21 | | 第六節 | 股東會的表決和決議 | 25 | | 第五章 | 董事會 | 30 | | 第一節 | 董事 | 30 | | 第二節 | 董事會 | 35 | | 第六章 | 總經理及其他高級管理人員 | 39 | | 第七章 | 監事會 | 41 | | 第一節 | 監事 | 41 | | 第二節 | 監事會 | 42 | | 第八章 | 財務會計制度、利潤分配和審計 | 43 | | 第一節 | 財務會計制度 | 43 | | 第二節 | 內部審 ...

长风药业(02652)将于10月8日(周三)在香港挂牌。截至发稿，利弗莫尔证券暗盘交易显示报价46港元，较招股价14.75港元上涨211.86%，每手500股，不计手 续费，每手赚15625港元。 -20.480 ● 价位 ● 均价 -238.85% 45.980 分时量 量:11000 98000 45.960 45.940 45.920 45.900 MACD(12,26,9) :- 2.087 DIF :- 0.261 DEA:0.783 MACD 45.880 45.860 45.840 45.820 16:15 18:30 1分 55 分时 EK • 行情来源: 利弗莫尔证券 • | 49,986 | 238.85% 十档 | | --- | --- | | | 46.480 | | | 46.460 | | | 46.440 | | | 46.420 | | | 46.400 | | 14.750 | 46.380 | | | 46.360 | | | 46.340 | | | 46.320 | | | 46.300 | | | 46.000 | ...

| 49,986 | 238.85% | 十档 | | --- | --- | --- | | | | 46.480 | | | | 46.460 | | | | 46.440 | | | | 46.420 | | | | 46.400 | | 14.750 | | 46.380 | | | | 46.360 | | | | 46.340 | | | | 46.320 | | | | 46.300 | | | | 46.000 | -20.480 ● 价位 ● 均价 -238.85% 45.980 分时量 量:11000 98000 45.960 45.940 45.920 45.900 MACD(12,26,9) :- 2.087 DIF :- 0.261 DEA:0.783 MACD 45.880 45.860 45.840 45.820 16:15 18:30 1分 55 分时 日K • 行情来源: 利弗莫尔证券 • 智通财经APP获悉，长风药业(02652)将于10月8日(周三)在香港挂牌。截至发稿，利弗莫尔证券暗盘交易显示报价46港元，较招股价14.75港元上涨211.86%， 每手500股，不计手 ...

Group 1 - The core viewpoint of the articles highlights the significant oversubscription of Changfeng Pharmaceutical's IPO, with a margin loan of at least HKD 339.6 billion and an oversubscription rate of 5,587 times, making it the second highest in the new stock market since the revised pricing mechanism was implemented [1][2] - Changfeng Pharmaceutical plans to globally offer 41.198 million H-shares, with 10% allocated for Hong Kong and 90% for international sales, at a price of HKD 14.75 per share, with trading expected to commence on October 8, 2025 [1] - The company specializes in the research, production, and commercialization of inhalation technology and drugs, focusing on respiratory diseases, and has received six product approvals from the National Medical Products Administration and the FDA, demonstrating its capabilities in clinical development and commercialization [1] Group 2 - Financially, Changfeng Pharmaceutical's revenue is projected to grow from RMB 349 million in 2022 to RMB 608 million in 2024, reflecting a compound annual growth rate of 31.9%, with gross profit expected to reach RMB 491 million, a year-on-year increase of approximately 7.2% [2] - The company benefits from operational efficiency due to economies of scale and aims to continue controlling administrative expenses, with the proportion of administrative costs to revenue expected to decline as the business expands [2]

Core Viewpoint - Changfeng Pharmaceutical (02652) has experienced significant oversubscription in its IPO, indicating strong investor interest and confidence in the company's growth potential in the inhalation drug market [1][2]. Group 1: IPO Details - The IPO subscription period for Changfeng Pharmaceutical was from September 26 to October 2, with at least HKD 339.6 billion in margin loans reported by October 2, leading to an oversubscription rate of 5,587 times compared to the initial fundraising target of HKD 60.77 million [1]. - The company plans to issue 41.198 million H-shares globally, with 10% allocated for Hong Kong and 90% for international investors, at a price of HKD 14.75 per share [1]. - The H-shares are expected to commence trading on the Hong Kong Stock Exchange on October 8, 2025 [1]. Group 2: Business Focus and Product Development - Changfeng Pharmaceutical specializes in the research, development, production, and commercialization of inhalation technologies and drugs, primarily targeting respiratory diseases [1]. - The company has received six product approvals from the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), showcasing its capabilities in clinical development, production, regulatory affairs, and commercialization [1]. Group 3: Financial Performance - The company's revenue is projected to grow from RMB 349 million in 2022 to RMB 608 million in 2024, reflecting a compound annual growth rate (CAGR) of 31.9% [2]. - Gross profit for 2024 is expected to reach RMB 491 million, representing a year-on-year increase of approximately 7.2% [2]. - The company benefits from economies of scale, leading to improved operational efficiency, and plans to continue controlling administrative expenses, which are expected to decrease as a proportion of revenue with business expansion [2].

Core Viewpoint - Beijing Shuanglu Pharmaceutical Co., Ltd. announced that its associate company, Changfeng Pharmaceutical Co., Ltd., is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares at a price of HKD 14.75 per share [1] Group 1 - The total number of shares offered in the global sale is 41.198 million [1] - The offering price per share is set at HKD 14.75 [1] - After the offering, Shuanglu Pharmaceutical will hold 15.165653 million shares of Changfeng Pharmaceutical, representing 3.68% of the total shares post-issuance [1] Group 2 - The lock-up period for Shuanglu Pharmaceutical's shares in Changfeng Pharmaceutical is 12 months [1] - According to regulations, Shuanglu Pharmaceutical will classify its equity stake in Changfeng Pharmaceutical as a financial asset [1] - The listing of Changfeng Pharmaceutical is expected to have a positive impact on Shuanglu Pharmaceutical's financial and operational results in 2025, subject to audit results [1]

Group 1 - The core point of the article is that Shuanglu Pharmaceutical (002038.SZ) announced that its associate company, Changfeng Pharmaceutical (02652), is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025 [1] - Changfeng Pharmaceutical plans to offer a total of 41.198 million shares in its global offering, with a price set at HKD 14.75 per share [1]

Core Viewpoint - The company 双鹭药业 (002038.SZ) announced that its associate 长风药业 (02652) is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 per share [1] Group 1 - 双鹭药业 holds a stake in 长风药业, which is preparing for its IPO [1] - 长风药业 plans to offer a total of 41.198 million shares in its global offering [1] - The offering price for each share is set at HKD 14.75 [1]

Group 1 - Double-Crane Pharmaceutical's associate company, Changfeng Pharmaceutical, is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, with stock code 02652.HK [1] - After the completion of the offering, Double-Crane Pharmaceutical will hold a total of 15.1657 million shares in Changfeng Pharmaceutical, which is expected to account for 3.68% of the total shares after issuance [1] Group 2 - LEO Holdings has submitted an application to the Hong Kong Stock Exchange on September 29, 2025, for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange [1]